Researchers use our
technologies in their quest
to cure diseases like cancer,
HIV, and Parkinson’s
mRNA Vectorization of Gene-Editing Proteins
Gene-editing proteins can be used to inactivate, repair or insert sequences in living cells. Conventional approaches using plasmids or viruses to express gene-editing proteins can result in low-efficiency editing and unwanted mutagenesis when an exogenous nucleic acid fragment is inserted at random locations in the genome.
Our scientists developed a technology that uses mRNA to express gene-editing proteins. This technology can enable dramatically higher efficiency gene editing, including in primary cells, than other approaches, without using viruses or DNA-based vectors that may cause unwanted mutagenesis. This technology can be used, for example, to generate allogeneic CAR-T therapies for the treatment of cancer in which mRNA encoding gene-editing proteins is used to inactivate the endogenous T-cell receptor to prevent therapeutic T cells from causing graft-versus-host disease (GvHD), and/or to inactivate a gene (e.g., CD52) to spare therapeutic T cells from a T-cell depletion regimen involving the use of a monoclonal antibody (e.g., anti-CD52). This technology can also be used to generate allogeneic stem cell-derived therapies in which mRNA encoding gene-editing proteins is used to inactivate one or more components of the human leukocyte antigen (HLA) complex to render the cells immuno-nonreactive or “stealth”, and/or to insert a donor sequence into a genomic safe harbor locus to enable controlled expression of an exogenous gene.
mRNA Vectorization of Gene-Editing Proteins is protected by U.S. Patent Number 10,662,410 (with additional patents pending in the U.S. and in other countries). Of note, the granted patent includes claims that are not limited by disease indication, cell type, target sequence, mRNA sequence or chemistry, or method of transfection.
- Ultra-high efficiency editing of T cells, fibroblasts, keratinocytes, and pluripotent stem cells
- Ultra-high specificity gene editing (e.g., express gene-editing proteins with 36-40-base target sequences)
- Virus-free and DNA-free gene editing
- Gene repair using a DNA-repair template
- Donor sequence insertion into a target genomic locus (e.g., TRAC, AAVS1 safe harbor, etc.)
- Gene-editing therapies (ex vivo and in vivo)
- Autologous and allogeneic engineered cell therapies (e.g., CAR-T, CAR-NK, stem cell-derived therapies, etc.)
- Combine with Factor’s mRNA Cell Reprogramming technology to generate models of genetic disease, gene-corrected patient-specific cell therapies, and allogeneic (i.e., immuno-nonreactive or “stealth”) cell therapies, including allogeneic pluripotent stem cell-derived CAR-T and CAR-NK cell therapies for the treatment of cancer, and engineered mesenchymal stem cell (MSC) therapies for regenerative medicine, wound-healing, inflammatory and auto-immune diseases, and tumor-targeting application
Figure 1. High-efficiency gene editing of TRAC and PD1 in human epidermal keratinocytes and human iPS cells.
Figure 2. High-efficiency gene editing of the AAVS1 genomic safe harbor locus in human iPS cells.